Egetis Therapeutics AB (publ) (EGTX.ST)
SEK 4.09
(1.11%)
SEK 4.09
(1.11%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 214.6 Million SEK | 290.89% |
| 2022 | 54.9 Million SEK | 30.0% |
| 2021 | 42.23 Million SEK | -84.02% |
| 2020 | 264.34 Million SEK | 949.09% |
| 2019 | 25.19 Million SEK | 11.12% |
| 2018 | 22.67 Million SEK | 94.52% |
| 2017 | 11.65 Million SEK | 69.61% |
| 2016 | 6.87 Million SEK | 58.77% |
| 2015 | 4.32 Million SEK | -66.21% |
| 2014 | 12.81 Million SEK | 215.75% |
| 2013 | 4.05 Million SEK | -37.74% |
| 2012 | 6.51 Million SEK | 67.36% |
| 2011 | 3.89 Million SEK | 159.12% |
| 2010 | 1.5 Million SEK | 448.39% |
| 2009 | 273.98 Thousand SEK | -15.32% |
| 2008 | 323.55 Thousand SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 227.5 Million SEK | 6.01% |
| 2024 Q2 | 245.2 Million SEK | 7.78% |
| 2023 Q1 | 47.4 Million SEK | -13.66% |
| 2023 Q3 | 67.2 Million SEK | 16.06% |
| 2023 Q2 | 57.9 Million SEK | 22.15% |
| 2023 Q4 | 214.6 Million SEK | 219.35% |
| 2023 FY | 214.6 Million SEK | 290.89% |
| 2022 Q3 | 35 Million SEK | 33.86% |
| 2022 FY | 54.9 Million SEK | 30.0% |
| 2022 Q4 | 54.9 Million SEK | 56.86% |
| 2022 Q1 | 35.76 Million SEK | -15.32% |
| 2022 Q2 | 26.14 Million SEK | -26.89% |
| 2021 Q1 | 240.24 Million SEK | -9.11% |
| 2021 Q3 | 222.96 Million SEK | -12.6% |
| 2021 FY | 42.23 Million SEK | -84.02% |
| 2021 Q4 | 42.23 Million SEK | -81.06% |
| 2021 Q2 | 255.1 Million SEK | 6.18% |
| 2020 FY | 264.34 Million SEK | 949.09% |
| 2020 Q3 | 22.56 Million SEK | -17.06% |
| 2020 Q4 | 264.34 Million SEK | 1071.36% |
| 2020 Q2 | 27.2 Million SEK | -15.1% |
| 2020 Q1 | 32.04 Million SEK | 27.19% |
| 2019 Q1 | 23.59 Million SEK | 4.07% |
| 2019 FY | 25.19 Million SEK | 11.12% |
| 2019 Q4 | 25.19 Million SEK | 7.71% |
| 2019 Q3 | 23.39 Million SEK | -4.88% |
| 2019 Q2 | 24.59 Million SEK | 4.22% |
| 2018 Q4 | 22.67 Million SEK | 77.95% |
| 2018 FY | 22.67 Million SEK | 94.52% |
| 2018 Q3 | 12.74 Million SEK | -40.55% |
| 2018 Q2 | 21.43 Million SEK | 76.42% |
| 2018 Q1 | 12.14 Million SEK | 4.21% |
| 2017 Q1 | 9.33 Million SEK | 35.85% |
| 2017 Q4 | 11.65 Million SEK | -46.91% |
| 2017 Q3 | 21.95 Million SEK | 293.07% |
| 2017 FY | 11.65 Million SEK | 69.61% |
| 2017 Q2 | 5.58 Million SEK | -40.17% |
| 2016 Q2 | 12.02 Million SEK | 245.33% |
| 2016 Q3 | 4.76 Million SEK | -60.33% |
| 2016 Q4 | 6.87 Million SEK | 44.12% |
| 2016 FY | 6.87 Million SEK | 58.77% |
| 2016 Q1 | 3.48 Million SEK | -19.59% |
| 2015 Q1 | 9.94 Million SEK | -22.37% |
| 2015 Q4 | 4.32 Million SEK | -23.79% |
| 2015 FY | 4.32 Million SEK | -66.21% |
| 2015 Q2 | 5.61 Million SEK | -43.54% |
| 2015 Q3 | 5.68 Million SEK | 1.16% |
| 2014 Q3 | 7.81 Million SEK | 131.96% |
| 2014 Q1 | 2.43 Million SEK | -40.0% |
| 2014 FY | 12.81 Million SEK | 215.75% |
| 2014 Q4 | 12.81 Million SEK | 64.02% |
| 2014 Q2 | 3.36 Million SEK | 38.33% |
| 2013 Q3 | 3.01 Million SEK | 3.82% |
| 2013 Q4 | 4.05 Million SEK | 34.61% |
| 2013 Q2 | 2.9 Million SEK | -35.99% |
| 2013 Q1 | 4.53 Million SEK | -30.4% |
| 2013 FY | 4.05 Million SEK | -37.74% |
| 2012 Q2 | 3.92 Million SEK | -4.35% |
| 2012 Q3 | 5.43 Million SEK | 38.56% |
| 2012 Q1 | 4.1 Million SEK | 5.37% |
| 2012 Q4 | 6.51 Million SEK | 19.85% |
| 2012 FY | 6.51 Million SEK | 67.36% |
| 2011 Q2 | 5.19 Million SEK | 472.11% |
| 2011 FY | 3.89 Million SEK | 159.12% |
| 2011 Q4 | 3.89 Million SEK | 88.52% |
| 2011 Q3 | 2.06 Million SEK | -60.24% |
| 2011 Q1 | 907.83 Thousand SEK | -39.58% |
| 2010 Q4 | 1.5 Million SEK | 0.0% |
| 2010 FY | 1.5 Million SEK | 448.39% |
| 2009 FY | 273.98 Thousand SEK | -15.32% |
| 2008 FY | 323.55 Thousand SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Calliditas Therapeutics AB (publ) | 1.56 Billion SEK | 86.294% |
| Camurus AB (publ) | 414.81 Million SEK | 48.267% |
| Mendus AB (publ) | 51.22 Million SEK | -318.936% |
| Lipum AB (publ) | 7.53 Million SEK | -2746.909% |
| NextCell Pharma AB | 13.68 Million SEK | -1467.676% |
| Simris Alg AB (publ) | 148.93 Million SEK | -44.087% |
| Elicera Therapeutics AB (publ) | 13.77 Million SEK | -1458.282% |
| Active Biotech AB (publ) | 13.4 Million SEK | -1501.493% |
| Amniotics AB (publ) | 10.54 Million SEK | -1934.702% |
| Asarina Pharma AB (publ) | 4.42 Million SEK | -4748.622% |
| BioArctic AB (publ) | 139.5 Million SEK | -53.832% |
| Cantargia AB (publ) | 54.97 Million SEK | -290.395% |
| Scandinavian ChemoTech AB (publ) | 3.83 Million SEK | -5491.454% |
| CombiGene AB (publ) | 4.15 Million SEK | -5063.62% |
| Diamyd Medical AB (publ) | 71.11 Million SEK | -201.752% |
| Genovis AB (publ.) | 98.04 Million SEK | -118.875% |
| Guard Therapeutics International AB (publ) | 18.49 Million SEK | -1060.376% |
| Isofol Medical AB (publ) | 19.16 Million SEK | -1019.808% |
| Intervacc AB (publ) | 21.68 Million SEK | -889.852% |
| Kancera AB (publ) | 17.97 Million SEK | -1093.681% |
| Karolinska Development AB (publ) | 11.56 Million SEK | -1754.957% |
| LIDDS AB (publ) | 3.75 Million SEK | -5613.525% |
| Lipigon Pharmaceuticals AB (publ) | 5.15 Million SEK | -4060.527% |
| Magle Chemoswed Holding AB (publ) | 123.97 Million SEK | -73.094% |
| OncoZenge AB (publ) | 1.69 Million SEK | -12530.959% |
| Saniona AB (publ) | 86.08 Million SEK | -149.294% |
| Vicore Pharma Holding AB (publ) | 40.85 Million SEK | -425.221% |
| Xbrane Biopharma AB (publ) | 482.17 Million SEK | 55.493% |
| Xintela AB (publ) | 14.01 Million SEK | -1431.217% |
| Xspray Pharma AB (publ) | 71.85 Million SEK | -198.678% |
| Ziccum AB (publ) | 6.38 Million SEK | -3259.424% |
| Modus Therapeutics Holding AB (publ) | 2.35 Million SEK | -8997.075% |
| Alligator Bioscience AB (publ) | 106.59 Million SEK | -101.323% |
| Sprint Bioscience AB (publ) | 34.6 Million SEK | -520.177% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 26.7 Million SEK | -703.505% |
| Corline Biomedical AB | 6.78 Million SEK | -3060.996% |
| IRLAB Therapeutics AB (publ) | 61.35 Million SEK | -249.756% |
| Bio-Works Technologies AB (publ) | 16.11 Million SEK | -1231.513% |
| Aptahem AB (publ) | 8.99 Million SEK | -2285.02% |
| Infant Bacterial Therapeutics AB (publ) | 46.18 Million SEK | -364.703% |
| Fluicell AB (publ) | 8.91 Million SEK | -2307.179% |
| Biovica International AB (publ) | 34.76 Million SEK | -517.252% |
| Spago Nanomedical AB (publ) | 11.66 Million SEK | -1739.218% |
| AcouSort AB (publ) | 10.37 Million SEK | -1967.836% |
| Abliva AB (publ) | 16.78 Million SEK | -1178.827% |
| 2cureX AB (publ) | 2.93 Million SEK | -7211.755% |
| I-Tech AB | 16.2 Million SEK | -1224.283% |
| Hansa Biopharma AB (publ) | 1.18 Billion SEK | 81.904% |
| Cyxone AB (publ) | 4.69 Million SEK | -4471.794% |
| ExpreS2ion Biotech Holding AB (publ) | 13.32 Million SEK | -1510.144% |
| Biosergen AB | 5.08 Million SEK | -4120.256% |
| Nanologica AB (publ) | 79.32 Million SEK | -170.526% |
| SynAct Pharma AB | 51.83 Million SEK | -314.014% |
| Annexin Pharmaceuticals AB (publ) | 7.94 Million SEK | -2599.711% |
| BioInvent International AB (publ) | 90.45 Million SEK | -137.25% |
| Stayble Therapeutics AB (publ) | 5.19 Million SEK | -4030.94% |
| Alzinova AB (publ) | 9.33 Million SEK | -2199.861% |
| Oncopeptides AB (publ) | 181.59 Million SEK | -18.173% |
| Pila Pharma AB (publ) | 1.79 Million SEK | -11862.096% |
| Ascelia Pharma AB (publ) | 12.74 Million SEK | -1583.93% |
| Diagonal Bio AB (publ) | 7.26 Million SEK | -2855.923% |